Document is current
Any future updates will be listed below
-
Authors
Oh, Chang-ki https://orcid.org/0000-0003-2489-4072
Piña-Crespo, Juan
Talantova, Maria
Carnevale, Lauren N. https://orcid.org/0000-0003-0451-0481
Stoneham, Charlotte https://orcid.org/0000-0003-3729-6936
Lewinski, Mary
Guatelli, John
Lipton, Stuart A. https://orcid.org/0000-0002-3490-1259
- License Information
-
More Information
Article History
Received: 4 January 2023
Accepted: 22 August 2023
First Online: 5 October 2023
Competing interests
: As in the original manuscript, the authors declare that S.A.L. is an inventor on patents for the use of memantine and various aminoadamantane nitrate compounds for neurodegenerative and neurodevelopmental disorders. He is also an inventor on composition of matter patents and use patents for aminoadamantane nitrate compounds in treating COVID-19 and other viral diseases. Per Harvard University guidelines, S.A.L. participates in a royalty-sharing agreement with his former institution, Boston Children’s Hospital/Harvard Medical School, which licensed the drug memantine (Namenda) to Forest Laboratories/Actavis/ Allergan/AbbVie for use in dementia. The aminoadamantane nitrate compounds are licensed to EuMentis Therapeutics, Inc. for both neurologic disease and COVID-19.
